Enhanced Oral Bioavailability of Efavirenz by Solid Lipid Nanoparticles: In Vitro Drug Release and Pharmacokinetics Studies

Table 4

Physical characterization.

Formulation code	PDI	Particle size	Zeta potential	EE (%)
ESLN-0	0.455	362±2.1	−22.1	46.28±1.05
ESLN-1	0.334	267±2.2	−19.3	70.2±0.98
ESLN-2	0.315	213.4±2.4	−17.7	76.1±0.7
ESLN-3	0.234	124.5±3.2	−15.9	86±1.03

All data expressed as mean ± S.D.; 𝑛=3; 𝑃≤0.05.